0.693 USD 👎0.147 (-21.21%)
At close Fri Sep 30 2022
Bioxytran, Inc. [BIXT]
Other OTC exchange. Sector: Healthcare. Industry: Biotechnology. Location United States, Newton.
67,242,968 USD
Marketcap
PE:.
BETA (5y):0.529
EPS:-0.026
Profits
Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
BioXyTran Inc. is a biopharmaceutical company focused on developing anti-necrosis treatment for stroke and ischemia.
© 2022 avazzy.com. All rights reserved
Make with 🤎 and ☕ for you!
Investing involves risk, including possible loss of principal.
The strategies discussed are strictly for illustrative and educational purposes and are not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. There is no guarantee that any strategies discussed will be effective.
International investing involves risks, including risks related to foreign currency, limited liquidity, less government regulation and the possibility of substantial volatility due to adverse political, economic or other developments. These risks often are heightened for investments in emerging/ developing markets or in concentrations of single countries.